Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lol there has got to be something else but with the font change it is making it difficult to find
$CMGO & $AEYE both solid companies - good call
so far the I see on page 1
the original release starts with
OTC Markets Group, Inc.
304 Hudson Street
2nd Floor
New York, New York 10013
Re: Atlas Technology Group, Inc./Racing Limos International, Inc. Annual Information and Disclosure Statement Year Ended December 31, 2012
the new release has
OTC Markets Group, Inc.
304 Hudson Street
2nd Floor
New York, New York 10013
Re: Atlas Technology Group, Inc./Racing Limos International, Inc.
Annual Information and Disclosure Statement Year Ended December 31, 2012, as published on March 25, 2013 by OTC Disclosure & News Service on March 25, 2013
im looking but I cant find the difference yet, just the font so far
it says Revised opinion letter for 2012 annual report
otcmarket link for those that can access
http://www.otcmarkets.com/stock/ATYG/filings
well at least someone is home on the facebook page, as of last week
https://www.facebook.com/thedirectory
$SEEK
need to request MARA be on stockcharts.com
$MARA
absolutely - I may not like the SS, but I have no issue when it goes down :)
just to recap some numbers here
OS a/o March 27th: 6,250,705,874
OS a/o April 15th: 6,030,705,874
we are back to March 18 numbers....hmmmmm
(Sourced from sticky)
Share Structure as per pinksheets
a/o March 18, 2013
Authorized Shares......15,000,000,000
Shares Outstanding.....6,030,705,874
Float..........................5,269,348,854
a/o March 1, 2013
Authorized Shares......15,000,000,000
Shares Outstanding.....5,552,775,375
Float..........................4,791,414,966
a/o Feb 05, 2013
A/S 15,000,000,000
Shares Outstanding 4,136,775,375
Float 3,375,414,966
Previous Structure
December 06,2012
A/S count: 2,000,000,000
O/S count: 1,083,449,851
Restricted shares: 111,360,576
Float: 972,089,275
what about the argument of being able to grow your own tobacco or brew your own beer
you can, but do you....most don't
I agree with your take on the effects of mmj on pharma, why would they develop something that lowers there profits. Remember there is less money in full blown cures.
I don't believe, at this moment that it will be MJNA supplying the mmj but you never know
I appreciate the articulated point of view :)
very true and points taken
glad I am only watching at this moment and not actively holding or trading (no offense to any who are)
this def wont make me leave :)
$ARNA
holy after hours disaster $ARNA
Why expect a buy out and the have the money to get the people to develop it under there umbrella
Its hard pressed to believe only stinky pinkys are developing this
like big pharma would sit and wait....IMO I don't think so
Close to a loading zone - watching this closely daily
$ENTR
LMAO - that just made my day friend
person mark to man who makes me laugh
$ATYG
i'll be watching this one closely
im still waiting for him to answer me
my post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87136480
do i see 8's around the corner - moving back up $CMGO
damn - traders making a killing on this
kudos to the who ever is playing this like fiddle - well done trading
ummmm yea - how bout them yankees lmao $SEEK
no much in the way to get this back up
once the news flows forget about it, let the suckers sell all day down here lmao
$CMGO
OVERSOLD - UNDERVALUED and boy i cant wait for the market to catch on
just let me keep loading first ;)
$CMGO
what a joke - for peanuts too a measly 29k shares haha
i hope that was a free trade for whatever sucker did that
$CMGO
i wouldnt be suprised - im not sure how fast they are looking to sell
$CMGO
actions a little light to start the day hmmmmm ;)
$CMGO
Hmmm interesting - I had that happen in the past when what I was owed in shares didn't equal a round number, they gave me cash in lieu of, and equvilant to the value of the left over fractional share
$AEYE
I saw that - what a bunch of nonsense
$CMGO
where did everyone go? $MDBX
im not down or in but its a tough pill to swallow for those that were told and followed the buying instructions in the upper 20's and lower 30's
at this point they can still recoup and get back as the long as its not the company putting in the volume
its an interesting story here
$MJNA
from a chart standpoint(short play) or from an investment standpoint (long term)?
always appreciated :)
person mark for my friend - $AEYE on the move
very true fiend - but my simple advice - MMJ should not be part of a retirement portfolio, but part of a trading portfolio/investment portfolio.
still to risky to bet your retirement on(imo of course)
CBIS DD & Quick Info Sheet
iHub Board
http://investorshub.advfn.com/Cannabis-Science-Inc-CBIS-7105/
Quote
http://ih.advfn.com/p.php?pid=squote&symbol=CBIS
Company Website
http://cannabisscience.com/
SEC Filings
http://www.sec.gov/cgi-bin/browse-edgar?company=Cannabis+science&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
------------------------------------------------------------------
------------------------------------------------------------------
CBIS Cancer Treatment Review
Cannabis Science Receives New Photos & Information on Patient Three’s Previous Examinations & the Current Progress on his S...
May 16, 2012
….Cannabis Science continues to work closely with its third patient, who is self-treating his otherwise resistant Squamous Cell Carcinoma. The patient has seen dramatic improvements. He has been applying a topical cannabis extract to his cancer, and has seen a large reduction in the tumor masses. Dr. Melamede spoke with the patient this morning, who stated that 80% of the rim that remained from the large tumor on the left side of his head was now gone. The newly posted photo was from over a week ago…..
Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide new photographs of the existing treatment for patient three who has a “worst case” of treatment resistant, Squamous Cell Carcinoma. Cannabis Science has received positive feedback from both the patient and his Oncologist. These photos show the progressive reduction of the tumor masses that has occurred within the months of treatment.
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is happy to report that patient #2, who had a Squamous cell carcinoma on her arm, has received her biopsy report. It confirms what was visually apparent from the photo-documentation on our website. Her biopsy was free of cancer cells and she will not need any surgical procedure. Nevertheless, the patient will continue with her self-administered topical application of extracts for a while longer to minimize any chance of any surviving cancer cells in areas beyond what was biopsied.
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is monitoring the outstanding progress of the 3rd Self-Medicated Cannabis Patient with Clear Continued Improvement. This self-medicating patient has what his doctors describe as the worst case of squamous cell carcinoma the had ever seen. This patient’s tumors, while resistant to conventional treatment, continues to make obvious improvement with the use of cannabis extracts
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is monitoring the outstanding progress of the 3rd Self-Medicated Cannabis Patient with Clear Continued Improvement. This self-medicating patient has what his doctors describe as the worst case of squamous cell carcinoma the had ever seen. This patient’s tumors, while resistant to conventional treatment, continues to make obvious improvement with the use of cannabis extracts
Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to present the newest set of photographs showing evidence that the cancer cells appear to have been killed over the course of treatment from the 2nd self-administering cancer patient suffering from squamous cell carcinoma on her arm
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to introduce a 4th cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.
Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient, with previously treatment-resistant tumors, continues to make obvious improvement. The tumors appear to be dying and then healing after treatment with cannabis-based extracts
Today Cannabis Science receives the latest photographs for the 3rd self-administering cancer patient, mentioned in the previous news release dated, January 11, 2012. The treatment process is ongoing, but the results have been visually dramatic, the cannabis extracts have drastically shrunk some tumors and others are gone.
PROCEDURE AND RESULTS
The series of photos below documents the disappearance of a biopsied squamous cell tumor after self-administration of topical cannabis extracts over a 3 month period. After treatment with cannabis extract, the tumor was expelled from below the surface, killed, and healed.
The first picture shows a large tumor protruding a few inches above the surface of the patient's skull prior to treatment. The cannabis-based extract was applied into the holes and the surrounding tissue that are seen in this patient’s scalp that extended down to the skull. The second photograph shows the patient's head after receiving one of many radiation treatments. Subsequent photos demonstrate what appears to be the cannabis extract drawing out, and killing the cancer cells from these lesions.
While this patient's self-administered treatment with cannabis extracts is still in progress, the results after just two weeks of treatment are dramatic. Some of the tumors have disappeared and others have significantly shrunk to a fraction of their original size. Simultaneously, the patient has had a significant decrease in pain, improved sleeping (the 1st full night of sleep in 3 years), as well as relief from the symptoms of multiple sclerosis that the patient also suffers from. This self-treatment is a work in progress.
Cannabis Science is showing the general public unbiased evidence as we acquire it independent of the final outcome. As the treatment continues, and physician determinations are made, we will continue to update you so that you can follow the effectiveness of this treatment as it progresses.
DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS), US biotech company developing pharmaceutical cannabis products. On March 9, 2011 Cannabis Science announced that we would follow up our press release with medical documentation regarding the effectiveness of our cannabis extracts for treating skin cancer as was documented photographically in our earlier press release of February 22, 2011. We are pleased to announce that we have physician’s documentation that confirms the successful treatment of basal cell carcinoma that resulted from the application of a topical cannabis extract.
Please visit www.cannabisscience.com to view the “Breaking News” of the successful results and images of the self-administered cancer treatments along with the physician's documentation after 4pm EST., today.
Currently, there is a tremendous amount of controversy with respect to the effects that cannabinoids have on cancers. Endocannabinoids, phytocannabinoids, and synthetic cannabinoids have demonstrated cancer killing and anti-metastatic properties in tissue culture and in animal models. While formal, proper, FDA approved clinical trials that would prove or disprove the therapeutic potential of cannabis extracts for treating cancers; trials have not been carried out. Nevertheless, a significant number of anecdotal observations have accumulated that suggest people suffering from a variety of cancers appear to have been cured by ingesting what is known as “Rick Simpson's hemp oil”.
There is widespread ignorance regarding the endocannabinoid system by medical professionals and laymen alike. The first hint that an endocannabinoid system existed resulted from an experiment published in 1988. Because of the endemic political and social bias against medical cannabis, nurtured by decades of misinformation, Cannabis Science has chosen a path that we feel will have the greatest probability of successfully traversing the FDA approval process. Our initial test product will only be topical, and will be formulated to reduce any internal consumption and thus reduce any abuse potential. With these considerations in mind, we will initially seek FDA approval for topically applied cannabis extracts for the treatment of basal cell carcinoma, a common form of skin cancer.
According to the National Cancer Institute ( www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001827/), basal cell carcinoma is the most frequently occurring cancer in the United States. Because of the horrific impact that cancer in general has on so many people worldwide, Cannabis Science has decided to make basal cell carcinoma its first target for clinical trial.
here it is for all those who keep asking about it - hope your here to see it ;)
$CBIS
CBIS DD & Quick Info Sheet
iHub Board
http://investorshub.advfn.com/Cannabis-Science-Inc-CBIS-7105/
Quote
http://ih.advfn.com/p.php?pid=squote&symbol=CBIS
Company Website
http://cannabisscience.com/
SEC Filings
http://www.sec.gov/cgi-bin/browse-edgar?company=Cannabis+science&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
------------------------------------------------------------------
------------------------------------------------------------------
CBIS Cancer Treatment Review
Cannabis Science Receives New Photos & Information on Patient Three’s Previous Examinations & the Current Progress on his S...
May 16, 2012
….Cannabis Science continues to work closely with its third patient, who is self-treating his otherwise resistant Squamous Cell Carcinoma. The patient has seen dramatic improvements. He has been applying a topical cannabis extract to his cancer, and has seen a large reduction in the tumor masses. Dr. Melamede spoke with the patient this morning, who stated that 80% of the rim that remained from the large tumor on the left side of his head was now gone. The newly posted photo was from over a week ago…..
Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide new photographs of the existing treatment for patient three who has a “worst case” of treatment resistant, Squamous Cell Carcinoma. Cannabis Science has received positive feedback from both the patient and his Oncologist. These photos show the progressive reduction of the tumor masses that has occurred within the months of treatment.
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is happy to report that patient #2, who had a Squamous cell carcinoma on her arm, has received her biopsy report. It confirms what was visually apparent from the photo-documentation on our website. Her biopsy was free of cancer cells and she will not need any surgical procedure. Nevertheless, the patient will continue with her self-administered topical application of extracts for a while longer to minimize any chance of any surviving cancer cells in areas beyond what was biopsied.
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is monitoring the outstanding progress of the 3rd Self-Medicated Cannabis Patient with Clear Continued Improvement. This self-medicating patient has what his doctors describe as the worst case of squamous cell carcinoma the had ever seen. This patient’s tumors, while resistant to conventional treatment, continues to make obvious improvement with the use of cannabis extracts
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is monitoring the outstanding progress of the 3rd Self-Medicated Cannabis Patient with Clear Continued Improvement. This self-medicating patient has what his doctors describe as the worst case of squamous cell carcinoma the had ever seen. This patient’s tumors, while resistant to conventional treatment, continues to make obvious improvement with the use of cannabis extracts
Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to present the newest set of photographs showing evidence that the cancer cells appear to have been killed over the course of treatment from the 2nd self-administering cancer patient suffering from squamous cell carcinoma on her arm
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to introduce a 4th cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.
Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient, with previously treatment-resistant tumors, continues to make obvious improvement. The tumors appear to be dying and then healing after treatment with cannabis-based extracts
Today Cannabis Science receives the latest photographs for the 3rd self-administering cancer patient, mentioned in the previous news release dated, January 11, 2012. The treatment process is ongoing, but the results have been visually dramatic, the cannabis extracts have drastically shrunk some tumors and others are gone.
PROCEDURE AND RESULTS
The series of photos below documents the disappearance of a biopsied squamous cell tumor after self-administration of topical cannabis extracts over a 3 month period. After treatment with cannabis extract, the tumor was expelled from below the surface, killed, and healed.
The first picture shows a large tumor protruding a few inches above the surface of the patient's skull prior to treatment. The cannabis-based extract was applied into the holes and the surrounding tissue that are seen in this patient’s scalp that extended down to the skull. The second photograph shows the patient's head after receiving one of many radiation treatments. Subsequent photos demonstrate what appears to be the cannabis extract drawing out, and killing the cancer cells from these lesions.
While this patient's self-administered treatment with cannabis extracts is still in progress, the results after just two weeks of treatment are dramatic. Some of the tumors have disappeared and others have significantly shrunk to a fraction of their original size. Simultaneously, the patient has had a significant decrease in pain, improved sleeping (the 1st full night of sleep in 3 years), as well as relief from the symptoms of multiple sclerosis that the patient also suffers from. This self-treatment is a work in progress.
Cannabis Science is showing the general public unbiased evidence as we acquire it independent of the final outcome. As the treatment continues, and physician determinations are made, we will continue to update you so that you can follow the effectiveness of this treatment as it progresses.
DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS), US biotech company developing pharmaceutical cannabis products. On March 9, 2011 Cannabis Science announced that we would follow up our press release with medical documentation regarding the effectiveness of our cannabis extracts for treating skin cancer as was documented photographically in our earlier press release of February 22, 2011. We are pleased to announce that we have physician’s documentation that confirms the successful treatment of basal cell carcinoma that resulted from the application of a topical cannabis extract.
Please visit www.cannabisscience.com to view the “Breaking News” of the successful results and images of the self-administered cancer treatments along with the physician's documentation after 4pm EST., today.
Currently, there is a tremendous amount of controversy with respect to the effects that cannabinoids have on cancers. Endocannabinoids, phytocannabinoids, and synthetic cannabinoids have demonstrated cancer killing and anti-metastatic properties in tissue culture and in animal models. While formal, proper, FDA approved clinical trials that would prove or disprove the therapeutic potential of cannabis extracts for treating cancers; trials have not been carried out. Nevertheless, a significant number of anecdotal observations have accumulated that suggest people suffering from a variety of cancers appear to have been cured by ingesting what is known as “Rick Simpson's hemp oil”.
There is widespread ignorance regarding the endocannabinoid system by medical professionals and laymen alike. The first hint that an endocannabinoid system existed resulted from an experiment published in 1988. Because of the endemic political and social bias against medical cannabis, nurtured by decades of misinformation, Cannabis Science has chosen a path that we feel will have the greatest probability of successfully traversing the FDA approval process. Our initial test product will only be topical, and will be formulated to reduce any internal consumption and thus reduce any abuse potential. With these considerations in mind, we will initially seek FDA approval for topically applied cannabis extracts for the treatment of basal cell carcinoma, a common form of skin cancer.
According to the National Cancer Institute ( www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001827/), basal cell carcinoma is the most frequently occurring cancer in the United States. Because of the horrific impact that cancer in general has on so many people worldwide, Cannabis Science has decided to make basal cell carcinoma its first target for clinical trial.
looks like I need to set up my email alerts with Scotty in regards to $AEYE
def appreciated, thanks for sharing :)
$AEYE
I have to agree - there is money to be made but imo you have to be quick on the trigger because this could end any minute
again this is all my opinion
I like the idea behind MJNA but something about thus company has me hesitant
Play the game or get burnt but never get married - The OTC
$MJAN
very true - the company is good like that IMO - no pump or PR blitz
just detailed info about the company progress in official filings
pretty sweet imo compared to what I've seen in my time in the OTC